Sunitinib Malate Patent Expiration
Sunitinib Malate is Used for treating gastrointestinal stromal tumors and protein kinase related disorders, such as renal cell carcinoma and advanced pancreatic neuroendocrine tumors. It was first introduced by Cp Pharmaceuticals International Cv
Sunitinib Malate Patents
Given below is the list of patents protecting Sunitinib Malate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sutent |
US6573293 (Pediatric) | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Aug 15, 2021
(Expired) | Cppi Cv |
| Sutent |
US7125905 (Pediatric) | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Aug 15, 2021
(Expired) | Cppi Cv |
| Sutent |
US7211600 (Pediatric) | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
Jun 22, 2021
(Expired) | Cppi Cv |
| Sutent | US6573293 | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Feb 15, 2021
(Expired) | Cppi Cv |
| Sutent | US7125905 | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Feb 15, 2021
(Expired) | Cppi Cv |
| Sutent | US7211600 | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
Dec 22, 2020
(Expired) | Cppi Cv |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Sunitinib Malate's patents.
Latest Legal Activities on Sunitinib Malate's Patents
Given below is the list recent legal activities going on the following patents of Sunitinib Malate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Oct, 2018 | US7211600(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Mar, 2018 | US7125905(Litigated) |
| Patent Term Extension Certificate Critical
| 06 Apr, 2016 | US6573293(Litigated) |
| Patent Term Extension Certificate Critical
| 17 Nov, 2015 | US6573293(Litigated) |
| Notice of Final Determination -Eligible | 16 Jun, 2015 | US6573293(Litigated) |
| Notice of Final Determination -Eligible | 23 Apr, 2015 | US6573293(Litigated) |
| FDA Final Eligibility Letter Critical
| 21 Jan, 2015 | US6573293(Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 15 May, 2014 | US6573293(Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 02 May, 2014 | US6573293(Litigated) |
| Second letter to regulating agency to determine regulatory review period | 05 Sep, 2013 | US6573293(Litigated) |
Sunitinib Malate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Sunitinib Malate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
